Edition:
United Kingdom

Xencor Inc (XNCR.OQ)

XNCR.OQ on NASDAQ Stock Exchange Global Market

32.28USD
23 Jan 2019
Change (% chg)

$-0.59 (-1.79%)
Prev Close
$32.87
Open
$33.02
Day's High
$33.70
Day's Low
$31.99
Volume
69,838
Avg. Vol
115,948
52-wk High
$48.31
52-wk Low
$20.96

Chart for

About

Xencor, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials... (more)

Overall

Beta: 2.15
Market Cap(Mil.): $1,163.30
Shares Outstanding(Mil.): 46.93
Dividend: --
Yield (%): --

Financials

  XNCR.OQ Industry Sector
P/E (TTM): -- 69.71 33.71
EPS (TTM): -0.87 -- --
ROI: -14.67 8.99 14.48
ROE: -15.16 10.14 15.99

BRIEF-Xencor Regains Ex-U.S. Commercial Rights To Xmab®13676, Cd20 X Cd3 Bispecific Antibody

* XENCOR REGAINS EX-U.S. COMMERCIAL RIGHTS TO XMAB®13676, CD20 X CD3 BISPECIFIC ANTIBODY

07 Jan 2019

Earnings vs. Estimates